Jansen Jacob

Recently, Jansen has taken  key roles in the following PharmaVentures M&A mandates:

  • Sanofi divestment of Slovak manufacturing site to Wood&Co (2013),
  • Merck divestment of R&D facility to BioCity (2012),
  • Sanofi divestment of 2 R&D sites to Covance (2010),
  • UCB sale of 3 manufacturing sites to Aesica (2010)

Jansen is a healthcare transactions professional with nearly 20 years in the life science sector with expertise in M&A, licensing, business strategy, commercial due-diligence and deal structuring. At PharmaVentures, Jansen has played a key role in the divestment of manufacturing and R&D businesses on behalf of top 10 large pharmaceutical companies, resulting in multi-million dollar deals. Over the years he has also worked on a diverse range of assignments including licensing, valuation and strategy projects.

Fluent in Malayalam and Hindi, Jansen holds a chemistry degree from Gandhiji University, a PhD in Biochemistry from the University of Sussex and an MBA from Oxford Brookes University. 

Corporate-Advisory

Director

Mobile: 
+44 (0) 7951 205 420